Neuronetics Stock

Neuronetics Working Capital

The Working Capital of Neuronetics (STIM) as of Aug 7, 2026 is 14.13 M USD. In the previous year, Working Capital was 12.54 M USD — a change of 12.70% (higher).

Working Capital

14.13 MUSD

YoY

12.70%

Last updated:

Working Capital of Neuronetics is 2026 14.13 M USD. Working Capital of Neuronetics was 2025 12.54 M USD. It decreases by 12.70% higher compared to the previous year.
Access this data via the Eulerpool API

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuronetics stock

Working Capital of Neuronetics is 14.13 M USD in 2026.

Working Capital of Neuronetics changed from 12.54 M USD to 14.13 M USD, representing a 12.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Neuronetics since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Neuronetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Neuronetics

All Key Metrics — Neuronetics